Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „vedolizumab“
Suchtreffer
Begriffe & Kennungen
Entyvio · 4.5 · 24 Vedolizumab has been studied in adult ulcerative colitis and Crohn’s disease patients with concomitant admi
Eintrag öffnenEntyvio · 4.5 · In adult patients with pouchitis, vedolizumab has been co-administered with antibiotics (see section 5.1). The
Eintrag öffnenEntyvio · 4.5 · Live vaccines, in particular live oral vaccines, should be used with caution concurrently with vedolizumab (se
Eintrag öffnenEntyvio · 4.5 · Live vaccines, in particular live oral vaccines, should be used with caution concurrently with vedolizumab (se
Eintrag öffnenEntyvio · 4.5 · The effect of vedolizumab on the pharmacokinetics of commonly co-administered medicinal compounds has not been
Eintrag öffnenEntyvio · 4.5 · Vedolizumab has been studied in adult ulcerative colitis and Crohn’s disease patients with concomitant adminis
Eintrag öffnenEntyvio · 4.8 · 27 In clinical studies with intravenous and subcutaneous vedolizumab, the rate of infections in vedolizumab-tr
Eintrag öffnenEntyvio · 4.8 · 9 In the EARNEST controlled study (pouchitis) with intravenous vedolizumab, only 1 out of 51 subjects (2.0%) i
Eintrag öffnenEntyvio · 4.8 · In EARNEST controlled study (pouchitis) with intravenous vedolizumab, hypersensitivity reactions, including IR
Eintrag öffnenEntyvio · 4.8 · In GEMINI 1 and 2 controlled studies (ulcerative colitis and Crohn’s disease) with intravenous vedolizumab, th
Eintrag öffnenEntyvio · 4.8 · In GEMINI 1 and 2 controlled studies (ulcerative colitis and Crohn’s disease), 4% of intravenous vedolizumab-t
Eintrag öffnenEntyvio · 4.8 · In GEMINI 1 and 2 controlled studies with intravenous vedolizumab, the rate of infections was 0.85 per patient
Eintrag öffnenEntyvio · 4.8 · In GEMINI 1 and 2 controlled studies with intravenous vedolizumab, the rate of serious infections was 0.07 per
Eintrag öffnenEntyvio · 4.8 · In GEMINI 1 and 2 controlled studies with intravenous vedolizumab, the rate of serious infections was 0.07 per
Eintrag öffnenEntyvio · 4.8 · In clinical studies with intravenous and subcutaneous vedolizumab, a slightly higher incidence of serious infe
Eintrag öffnenEntyvio · 4.8 · In clinical studies with intravenous vedolizumab (ulcerative colitis and Crohn’s disease), a slightly higher i
Eintrag öffnenEntyvio · 4.8 · In clinical studies with intravenous vedolizumab (ulcerative colitis and Crohn’s disease), the rate of infecti
Eintrag öffnenEntyvio · 4.8 · In clinical studies with subcutaneous vedolizumab, the rate of infections was 0.26 per patient year in vedoliz
Eintrag öffnenEntyvio · 4.8 · In clinical studies with subcutaneous vedolizumab, the rate of serious infections was 0.02 per patient year in
Eintrag öffnenEntyvio · 4.8 · In controlled and open-label studies in adults with intravenous vedolizumab, serious infections have been repo
Eintrag öffnen